Emerging Strategies to Overcome Resistance in Pancreatic Cancer

In an interview with Targeted Oncology, Linda Y. Wu, MD, assistant professor of Medicine at Columbia University Irving Medical Center, discusses the ongoing challenge of therapeutic resistance in pancreatic cancer and emerging strategies to address it. Resistance continues to limit the effectiveness of chemotherapy, immunotherapy, and newer targeted approaches, making it a critical focus of current research.

Chemotherapy resistance remains a well-known obstacle in pancreatic cancer. To overcome this, investigators are exploring innovative delivery strategies that enhance drug concentration directly at the tumor site. These include localized approaches, such as catheter-based delivery systems, and targeted therapies designed to bind specific tumor markers and deliver cytotoxic agents more precisely. These methods aim to improve efficacy while minimizing systemic toxicity and are currently being evaluated in clinical trials.

Immunotherapy has historically shown limited success in pancreatic cancer due to its immunologically “cold” tumor microenvironment. To counter this, novel combination strategies are under investigation. These include agents that help recruit immune cells into the tumor, improving immune recognition and response. Early-phase studies are assessing whether such approaches can enhance the activity of immunotherapy in this difficult-to-treat disease.

Targeted therapies represent a promising but still developing area in pancreatic cancer. Although no therapies have yet achieved widespread regulatory approval in this setting, ongoing research is focused on identifying resistance mechanisms and designing rational combination strategies to prolong treatment responses. Lessons learned from other malignancies highlight the importance of anticipating resistance and developing next-line options.